BNET Industries
Last Fiscal Year Sales:$382.2M
- Public
- US
Dow Jones Description
Sciele Pharma, Inc. is a pharmaceutical company specializing in sales, marketing and development of branded prescription products focused on Cardiovascular, Diabetes, Women's Health and Pediatrics. The Company's Cardiovascular and Diabetes products treat patients with high cholesterol, hypertension, high triglycerides, unstable angina and Type 2 diabetes; its Women's Health products are designed to improve the health and well-being of women and mothers and their babies; and its Pediatrics products treat allergies, asthma, coughs and colds, and attention deficit/hyperactivity disorder (ADHD). Founded in 1992 and headquartered in Atlanta, Georgia, Sciele Pharma employs more than 1,000 people. The Company's success is based on placing the needs of patients first, improving health and quality of life, and implementing its business platform - an Entrepreneurial Spirit, Innovation, Execution Excellence, Simplicity, and Teamwork. On October 9,2008, Shionogi & Co., Ltd. ("Shionogi") and Sciele Pharma, Inc. ("Sciele") announced the completion of Shionogi's acquisition of Sciele for $31.00 USD per share in cash. Shionogi completed the acquisition through a cash tender offer followed by short-form merger of the indirect wholly owned subsidiary of Shionogi with and into Sciele. Sciele is now an indirect wholly owned subsidiary of Shionogi.
Number of Employees 920
Contact Information
5 Concourse Pkwy Ste 1800
Atlanta, Georgia 30328
(770) 442-9707
Peer Companies
NAICS Code Drugs and Druggists' Sundries Merchant Wholesalers: 424210
Recent Events
-
Week of Nov. 16, 2009: GSK and Nabi Form Nicotine Vaccine Agreement; Eli Lilly Research...
-
Bitter pill for Atlanta: 200 more pharma jobs lost
-
Willkie Farr and Paul Weiss on $2.6 Billion Japanese Pharma Deal
-
UPDATE 1-Plethora sells lead drug rights, cuts debt by 90 pct
News & Analysis
Filter by
sciele pharma inc. - All News and Analysis
Shionogi Completes Acquisition of Sciele
- 2008-10-09
OSAKA, Japan & ATLANTA -- On October 9, 2008, Shionogi & Co., Ltd. ("Shionogi") and Sciele Pharma, Inc. ("Sciele") (NASDAQ: SCRX) announced the completion of Shionogi's acquisition of Sciele for US$31.00 per share in cash. Shionogi completed the acquisition through a cash tender offer followed by short-form merger of the...
Underdog Smallcaps: Potential Short Squeezes
Seeking Alpha
- 2008-09-14
J Clinton Hill submits: Most bullies like to pick on smaller guys who often can do little to resist their sheer size and brute strength. The market is no exception and its bullies are the hedge funds and professional traders who typically "gang up" against smallcap stocks. Yet, as...
Eli Lilly's Brewing Battle With Bristol-Myers
Seeking Alpha
- 2008-09-07
Mike Huckman submits: Last week I blogged about Eli Lilly's LLY "Coming Soon" banner ad I spotted in the online edition of The New England Journal of Medicine. It's designed to generate buzz about the company's crucial new bloodthinner that could win Food and Drug Administration approval this month....
Has Lilly's Effient Been FDA Approved?
Seeking Alpha
- 2008-09-03
Mike Huckman submits: I'm not gonna blog about the new Vytorin studies as there's been a plethora of coverage all over, including on CNBC. The only thing I wanted to mention was that while I was on the New England Journal of Medicine Web site on Monday preparing...
Pharma Merger: Japan?s Shionogi Buys Atlanta's Sciele for $1.42 Billion
Seeking Alpha
- 2008-09-02
Ron Haruni submits: Shionogi & Co. (SGIOF.PK), a major Japanese drug manufacturer and US-based specialty pharmaceutical company Sciele Pharma, Inc. SCRX, announced on Monday a definitive agreement under which Shionogi will acquire Atlanta-based Sciele Pharma Inc. shares, in an all-cash deal valued at $1.42 billion. The acquisition on the...
Sciele Pharma Inc. Q2 2008 Earnings Call Transcript
Seeking Alpha
- 2008-07-30
Question-and-Answer SessionOperator Thank you. Operators Instructions. Our first question this afternoon will come from Donald Ellis with Thomas Weisel Partners. Donald Ellis - Thomas Weisel Partners Thank you and good afternoon guys. Darrell I just wanted to kind of reconcile the old versus new guidance and the way I'd...
Sciele Pharma, Inc. Q1 2008 Earnings Call Transcript
Seeking Alpha
- 2008-04-30
Question-and-Answer SessionOperator Thank you. Operator Instructions. And, we will go first to Donald Ellis with Thomas Weisel Partners. Donald Ellis Good afternoon guys. I have a few questions. First for, I guess are on Sular. Can you just kind of give us an update...
Sciele Pharma Inc. Q4 2007 Earnings Call Transcript
Seeking Alpha
- 2008-03-07
Question-and-Answer Session Operator Operator Instructions And we will go first to Annabel Samimy - UBS. Annabel Samimy - UBS On the Sular, have you started drawing down inventories before January? It seems like the cardiovascular was a little bit lighter than we would have expected....
Sciele Pharma Q3 2007 Earnings Call Transcript
Seeking Alpha
- 2007-10-30
Question-and-Answer SessionOperator Operator Instructions. We'll go first to Adam Greene, JP Morgan. Adam Greene - JP Morgan Good evening, everyone. Darrell Borne Hi Adam, how are you? Adam Greene - JP Morgan Good. Few questions for you Darrell, on the guidance, you mentioned the excluding one time charges for...
- 1
Industry Transcripts by Seeking Alpha
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
-
Arena Pharmaceuticals Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ARNA
Glass Door
Pharma Industry Companies
| Company | Employer Rating |
| Johnson & Johnson |  |
| Merck | |
| Pfizer | |
| Novartis |  |
| Abbott Labs | |
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
- The 10 Weirdest Drug Stories of the Month 3 votes
